Abstract
Autoimmune haemolytic anaemia (AIHA) is characterised by the production of autoantibodies that target determinants on red blood cells. Current treatments rely on generalised immunosupression or cytotoxic treatments that may have potentially harmful side effects. Whilst the underlying cause of disease remains unknown, recent advances in our understanding of CD4+ helper T cell (Th) subsets that drive and control the autoimmune response have important implications for the development of novel immunotherapy. The effector arm of the adaptive immune response is now known to include at least three Th subsets: Th1, Th2 and the recently described Th17. In human AIHA, the targets of the autoimmune response in most patients, the Rhesus (Rh) proteins, have been identified and sequenced, providing the opportunity to study antigen specific responses. The effector Th response is dominated by Th1 cells that are under the control of IL-10 dependent regulatory cells (Tr1). These Th1 responses can be suppressed, with synthetic peptides that are recognised by the Tr1 cells. Such specificity would provide an extremely potent tool in the treatment of autoimmune disease. This review discusses the recent advances in our understanding of helper T cell subsets and the implications for the development of specific immunotherapy in autoimmune disease, using the well characterised responses in AIHA as an example.
Keywords: Autoimmune, autoimmune haemolytic anaemia, peptide therapy, helper T cell, regulatory T cell, cytokine
Cardiovascular & Hematological Disorders-Drug Targets
Title: Helper T Cells Point the Way to Specific Immunotherapy for Autoimmune Disease
Volume: 9 Issue: 3
Author(s): Andrew M. Hall, Mark A. Vickers, Robert N. Barker and Lars P. Erwig
Affiliation:
Keywords: Autoimmune, autoimmune haemolytic anaemia, peptide therapy, helper T cell, regulatory T cell, cytokine
Abstract: Autoimmune haemolytic anaemia (AIHA) is characterised by the production of autoantibodies that target determinants on red blood cells. Current treatments rely on generalised immunosupression or cytotoxic treatments that may have potentially harmful side effects. Whilst the underlying cause of disease remains unknown, recent advances in our understanding of CD4+ helper T cell (Th) subsets that drive and control the autoimmune response have important implications for the development of novel immunotherapy. The effector arm of the adaptive immune response is now known to include at least three Th subsets: Th1, Th2 and the recently described Th17. In human AIHA, the targets of the autoimmune response in most patients, the Rhesus (Rh) proteins, have been identified and sequenced, providing the opportunity to study antigen specific responses. The effector Th response is dominated by Th1 cells that are under the control of IL-10 dependent regulatory cells (Tr1). These Th1 responses can be suppressed, with synthetic peptides that are recognised by the Tr1 cells. Such specificity would provide an extremely potent tool in the treatment of autoimmune disease. This review discusses the recent advances in our understanding of helper T cell subsets and the implications for the development of specific immunotherapy in autoimmune disease, using the well characterised responses in AIHA as an example.
Export Options
About this article
Cite this article as:
Hall M. Andrew, Vickers A. Mark, Barker N. Robert and Erwig P. Lars, Helper T Cells Point the Way to Specific Immunotherapy for Autoimmune Disease, Cardiovascular & Hematological Disorders-Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/187152909789007043
DOI https://dx.doi.org/10.2174/187152909789007043 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Endothelial Progenitor Cells as Mediators of the Crosstalk between Vascular Repair and Immunity: Lessons from Systemic Autoimmune Diseases
Current Medicinal Chemistry Tacrolimus Treatment in Myasthenia Gravis
Current Drug Therapy Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Cellular and Molecular Mechanisms Involved in the Action of Vitamin D Analogs Targeting Vitiligo Depigmentation
Current Drug Targets Biological Therapies of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Assessment of Endothelial Function by Positron Emission Tomography
Current Cardiology Reviews Regulation of B Cell Activation by PECAM-1: Implications for the Development of Autoimmune Disorders
Current Pharmaceutical Design IL-17 and its Receptor Complex as Therapeutic Targets in Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Acquired Hemophilia as Initial Presentation in a Patient with Systemic Lupus Erythematosus
Current Rheumatology Reviews The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design The Role of STATs in Inflammation and Inflammatory Diseases
Current Pharmaceutical Design Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Cytokines and their Antagonists as Therapeutic Agents
Current Medicinal Chemistry